Lateral Flow Assays Market

Lateral Flow Assays Market by Application (Clinical Testing (Pregnancy, Infectious Diseases (Mosquito, Influenza, STI, Hepatitis, TB) Cardiac Marker Lipid Test) Veterinary, Food Safety) Product (Readers, Kits) Technique, End User - Global Forecast to (2022 - 2026)

Report Code: MD 4158 Dec, 2021, by marketsandmarkets.com

[400 Pages Report] The global lateral flow assays market is projected to reach USD 12.6 billion by 2026, at a CAGR of 2.0% during the forecast period. The high prevalence of infectious diseases worldwide, rapid growth in the geriatric population, growing demand for point-of-care testing, and rising use of home-based lateral flow assay devices are the major factors driving the growth of this market. On the other hand, reluctance among doctors and patients to change existing diagnostic procedures and the low accuracy of lateral flow assays are the key restraints.

Lateral Flow Assays Market

To know about the assumptions considered for the study, Request for Free Sample Report

Impact of Covid-19 on Lateral Flow Assays Market

To assess the impact of COVID-19 and provide market forecasts, scenario-based approaches are considered.

The lateral flow assays market has been positively impacted by the COVID-19 pandemic, as the need for the rapid diagnosis of the coronavirus infection has been the focus since the inception of the pandemic outbreak in December 2019. As the number of cases increased across regions, most of the major lateral flow assay market players have invested in R&D, as well as have entered into partnerships and agreements with other industry players and government agencies to develop lateral flow diagnostic solutions for the diagnosis of COVID-19 that would boost the growth of this market in the post-COVID-19 scenario.

In the optimistic scenario, the elevated focus and attention that the pandemic has generated for point-of-care diagnostics and diagnostic testing could be long-lasting. This would indicate that end-user awareness of the availability of lateral flow testing solutions for other disease conditions and purposes (for instance, food and environmental safety testing and drug development) would boost the growth of this market in the post-COVID-19 scenario.

Lateral Flow Assays Market Dynamics:

DRIVERS: High prevalence of infectious disease across the globe

Despite significant improvements in sanitation and medicine, the global prevalence of infectious diseases is still high. Although non-communicable diseases are the leading cause of morbidity and mortality, infectious diseases remain a major public health concern across the globe. The high prevalence of infectious diseases, such as HIV and malaria, coupled with the underdeveloped healthcare infrastructural facilities and increasing public awareness in developing countries, is expected to drive the adoption of lateral flow assay tests in these countries.

The high prevalence of infectious diseases, such as HIV and malaria, coupled with the underdeveloped healthcare infrastructural facilities and increasing public awareness in developing countries, is expected to drive the adoption of lateral flow assay tests in these countries. In addition, recent outbreaks of infectious diseases from the spread of viruses (such as Ebola, H1N1, and Zika) have highlighted the need for early disease detection capabilities, which is also expected to drive market growth. The current COVID-19 pandemic has resulted in high demand for rapid diagnostic testing through lateral flow technology, supporting the growth of this market in the coming year.

Rapidly increasing geriatric population

Age-related physiological changes and metabolic inefficiencies often result in chronic diseases such as cystic fibrosis, hepatitis, cardiovascular disorders, and cancer. Geriatric individuals (65 years and above) are more susceptible to these diseases and infectious diseases due to weakened immune systems. With the growing prevalence of chronic diseases, the emphasis on the effective and early diagnosis of diseases is rising. Lateral flow assay techniques are increasingly preferred for disease diagnosis due to their ability to detect symptoms in the early stages. The global rise in the geriatric population, coupled with the increasing patient pool for chronic diseases, translates into higher demand for lateral flow assay tests.

Furthermore, age-caused frailty has been an important concern during COVID-19 management. The risk of death from COVID-19 increases with both age and the presence of co-morbidities such as cardiovascular, pulmonary, or kidney disease, cancer, and obesity.

With the growing prevalence of chronic diseases, the emphasis on the effective and early diagnosis of diseases is rising. Lateral flow assay techniques are increasingly preferred for disease diagnosis due to their ability to detect symptoms in the early stages. The global rise in the geriatric population, coupled with the increasing patient pool for chronic diseases, translates into higher demand for lateral flow assay tests.

Growing usage of home-based lateral flow assays devices

Home-based lateral flow assay devices play a vital role in the management of cardiovascular and infectious diseases. These devices are also very useful in testing pregnancy and stigmatized conditions such as HIV as they potentially empower patients to perform self-tests in their homes. Hence, the increasing incidence of these diseases and the higher adoption of lateral flow assay tests in home care settings are expected to boost the demand for lateral flow assays.

During COVID-19, many companies launched home-based lateral flow assays for COVID-19 testing as people were afraid to get tested at diagnostic laboratories or hospitals due to the high rush, which supported the demand for home-based lateral flow assays. This led to the launches of several home-based assays. For example:

  • BinaxNOW COVID-19 Ag Card in August 2020 and Panbio rapid COVID-19 test in September 2020
  • Roche Diagnostics launched the SARS-CoV-2 Rapid Antigen test in September 2020.
  • Other tests launched during the COVID-19 include Sofia 2 Flu+ SARS Antigen FIA (Quidel Corporation), CLINITEST Rapid COVID-19 Antigen test (Danaher Corporation), and BD Veritor SARS CoV-2 Test (BD).

The pandemic also promoted cooperation between government bodies and key players to boost test availability. For instance, in August 2020, an agreement was signed between Abbott Laboratories (US) and the US government for 150 million home-based BinaxNOW COVID-19 tests.

Growing demand for point-of-care testing

Currently, most diagnostic tests performed across the globe are laboratory-based. However, lateral flow assay-based point-of-care (POC) tests are increasingly adopted to replace lengthy, conventional laboratory procedures. POC diagnostic tests require less complex infrastructure and training, owing to which the cost of these tests is lower than conventional laboratory diagnostic procedures. POC testing is anticipated to hold the greatest share in the lateral flow assay market because of its importance against a growing disease burden. For example, as per WHO, Global Tuberculosis Report 2020, ~1.4 million people died from tuberculosis-related illnesses in 2019; nearly 10 million individuals developed tuberculosis in 2019.

Infectious disease tests and cardiac markers are the fastest-growing segments in the POC testing market due to the increasing adoption of these tests in home care settings. Pregnancy and fertility tests, coagulation tests, and urine chemistry are common tests in the POC testing market. The lateral flow assay POC testing market has grown significantly in the last few years due to the increasing adoption of lateral flow assay testing products in home care settings. With the help of lateral flow assays, point-of-care testing is simple, rapid, inexpensive, convenient, and easy to interpret. These tests may be developed to show the existence of pathogens in a variety of samples, such as whole blood, plasma, serum, and saliva, thereby increasing their utility in point-of-care testing. Lateral flow assay point-of-care tests can also detect subclinically infected individuals by targeting biomarkers in some cases.

The rising prevalence of chronic diseases, technological advancements, growing patient awareness, and increasing access to new products are key factors driving this trend. Considering this, companies are increasingly focusing on developing innovative lateral flow assay-based POC devices for applications such as the confirmation of pregnancy (using hCG levels) and ovulation, screening for infectious diseases and drugs of abuse, and the measurement of protein markers in the blood to aid rapid clinical diagnostics of life-threatening events (such as heart attacks, strokes, and deep-vein thrombosis). For instance, in 2019, Abbott Laboratories (US) developed its ARCHITECT STAT Troponin I Blood Test, while Siemens AG developed the CLINITEK Microalbumin 2 strips for clinical diagnostics.

The rising demand for POC testing and the increasing focus on using lateral flow assay-based POC testing devices to achieve greater portability are expected to boost the growth of the lateral flow assays market during the forecast period.

Need for rapid diagnostic testing for COVID-19

The COVID-19 pandemic has spread rapidly across the globe since December 2019. With the number of individuals affected by the virus on the rise, the need for easy and fast detection has grown. Lateral flow assay tests have been developed to detect the antibody (IgM, IgG, or both) to the COVID-19 virus in patients’ blood or nasopharyngeal sample. Antibody lateral flow tests are kits used by specialists and not patients and require a drop of blood from a finger prick or a vein. These devices work by detecting the patient’s immune antibody response rather than the virus itself, unlike the RT-PCR (reverse transcription-polymerase chain reaction) and LAMP (loop-mediated isothermal amplification) testing techniques.

The rising number of COVID-19 cases globally and the need for rapid diagnosis for treatment and data collection is expected to accelerate the growth of the lateral flow assays market in the forecast period.

RESTRAINTS: Inconsistent results of lateral flow assays tests

Although easy to perform and more economical than laboratory tests, lateral flow assay tests have been observed to have lower accuracy. For instance, the SARS-CoV-2 antibody tests, based on the lateral flow technology, have shown a large margin of error. This has led to false negatives, which make it difficult to track the spread of the coronavirus. The low reliability of lateral flow assay tests has resulted in most clinicians and patients preferring molecular tests over rapid tests for the more accurate diagnosis of COVID-19 and other infectious disease.

OPPORTUNITY: Evolving application of lateral flow assays

Lateral flow assays have evolved rapidly in the last two decades and are routinely used in POC and diagnostic applications. Although lateral flow tests are widely being used for infectious disease diagnostics, the diagnosis of cardiac diseases, and veterinary applications, their use has increased in several new applications over the last few years. For instance, saliva diagnostics, behavioral health, agriculture (genetically modified organism detection and crop quality testing), biowarfare (anthrax detection), environmental testing (detection of contaminating enzymes in manufacturing plants), and food microbiology (detection of E. coli O157, Salmonella, Listeria, and other food spoilage organisms) have emerged as new application areas for lateral flow assays.

OraSure Technologies (US) is one of the major providers of lateral flow saliva testing. Salivary LFIAs have also penetrated the market for applications such as drugs-of-abuse testing, and several systems have been FDA-cleared for marketing; however, testing remains largely qualitative.

Salivary rapid tests have also been developed for infectious diseases. Companies such as SOMA Bioscience (UK) have developed quantitative saliva LFIAs for IgG, IgA, α-amylase, and cortisol; SOMA Bioscience’s salivary cortisol LFDs have been used in sports research. Medusa 19 Limited (UK) has developed the Rapid Saliva Protein Test (“RSPT”), which is a lateral flow saliva test to indicate the immune response to SARS-CoV-2 infection.

Rising demand for lateral flow assays in the food & beverage industry

Food safety issues and concerns for public health have led to the implementation of more stringent legislation for food safety in several countries. This resulted in an increased demand for pathogen and toxin tests in just about every segment of the food production industry—processed foods, meats, poultry, beverages, and dairy—and among all major food producers worldwide.

Earlier, most food safety tests were performed using lab-based traditional microbiology techniques, but rapid, on-the-spot tests have seen growing use in this area. These tests are used primarily for testing raw materials, interim products in the manufacturing process, and final products for bacteria such as Listeria, Salmonella, and E. coli. In August 2020, PerkinElmer launched a COVID-19 environmental surface testing kit to detect the virus in food processors. Furthermore, the food industry has also shown a demand for tests capable of detecting mycotoxins and allergens—such as RIDA QUICK rapid tests from R-Biopharm. Merck KGaA (Germany) provides Singlepath L’mono for detecting Listeria monocytogenes; Singlepath Salmonella for salmonella, and Singlepath Campylobacter for Campylobacter in foods.

Traditional microbiological testing requires finished products to sit in a warehouse pending test results that can take two to four days, whereas rapid technologies provide microbial test results in as little as 24 hours. These advantages, coupled with the implementation of the Hazard Analysis and Critical Control Points (HAACP) regulations that prescribe test procedures throughout the manufacturing process, are driving the demand for lateral flow tests in the food production industry. The combination of increased competition within the European food industry and the launch of the European validation system—MICROVAL—for alternative food testing methods will make it possible for Europe to catch up with the US in terms of using rapid food testing methods. In addition, large food-exporting countries such as Mexico and Brazil, as well as growing processed food industries in the Asia Pacific, will provide another growth avenue for players operating in the lateral flow assays market.

CHALLENGES: Limited reimbursements for lateral flow assay product

Owing to reimbursement issues, lateral flow assay-based diagnostic tests have witnessed limited adoption in several countries across the globe. The rise in healthcare expenditure is compelling insurance payers to question and analyze the necessity of new diagnostic tests. Also, payers are moving from fee-for-service reimbursement systems towards fee-for-value-based reimbursement systems. As a result, a diagnostic test that enables a clinician to decide whether to go for a particular treatment does not receive adequate reimbursement and is abandoned or underinvested.

Reimbursement issues are plaguing the growth of the lateral flow assay-based diagnostics industry in many countries. For instance, the National Health Service (NHS) accounts for ~75% of healthcare reimbursements throughout the UK. Within primary care in the NHS, reimbursement is available only for prescribed lateral flow assay devices, such as the CrAg lateral flow assays used to diagnose cryptococcosis. There is no separate policy for reimbursing non-prescribed lateral flow assay kits (such as cardiac markers and pregnancy kits).

Although there has been an increase in commercialized tests, most are not coded according to the Current Procedural Terminology (CPT). Diagnostic reports must follow specific medical coding protocols to offer the required information to a medical biller to process a reimbursement claim. Without coding and hence reimbursement, physicians will not opt for new diagnostic tests as they are more expensive than traditional methods. As limited reimbursements limit the funds generated from commercialized diagnostic tests, the funds required to finance R&D for new innovative diagnostic methods are limited. Also, due to the lack of reimbursement, patients are more inclined towards central lab tests.

Difficulties in procuring quality raw materials for the development of lateral flow assays tests

One of the challenging aspects of developing lateral flow assay tests is the procurement and qualification of antigens and antibodies, known as critical reagents. Antibodies to be used in assays must be tested for accuracy, specificity, stability, and reproducibility, as any defects in the reagent can result in failure of the assay. The qualification of a single lot of reagents requires more than 1,000 data points to be checked and verified. Another challenge is related to the stability testing of assays once an antibody or antibody pair is identified. For an assay to qualify as a commercial product, it should have a stable shelf life of 6 months, preferably extending to 18–24 months. Additional time, resources, and costs are involved in the correction of assays that fail stability testing. Consequently, this would result in creating a delayed time-to-market. These factors pose a challenge to the growth of the lateral flow assays market in the forecast period.

“Kits & Reagents segment accounted for the largest share in the lateral flow assays market.”

The lateral flow assays market is segmented into kits & reagents and lateral flow readers. In 2020, kits & reagents accounted for the larger share of the global lateral flow assays market. The large share of this segment can be attributed to the increasing application of lateral flow kits & reagents for POC testing, during the forecast period.

“Clinical Testing segment is expected to witness the fastest growth in the forecast period.”

The lateral flow assays market is segmented into clinical testing, veterinary diagnostics, food safety & environmental testing, and drug development & quality testing based on the application. The clinical testing segment accounted for the largest share of the lateral flow assays market in 2020. The large share of this segment can be attributed to the rising prevalence of chronic diseases and the increasing demand for patient-centric care.

“Sandwich assays technique accounted for the largest share of lateral flow assays market in 2020”

The lateral flow assay kits & reagents market is segmented into competitive assays, sandwich assays, and multiplex detection assays. The sandwich assays technique dominated the lateral flow assays market with a share in 2020. The large share of this segment can be attributed to its better assay sensitivity and specificity.

“Blood samples accounted for the largest share of lateral flow assays market in 2020”

The clinical testing lateral flow assays market is segmented into blood, urine, saliva, and other samples. Blood samples accounted for the largest market share in 2020. The use of blood samples in lateral flow tests for infectious diseases such as malaria, HIV, and syphilis; the rising awareness of rapid testing solutions; and easy detection of disease antibodies from blood samples are factors for the largest share of this segment.

“The hospitals & Clinics segment accounted for the largest share of lateral flow assays market in 2020”

Based on end users, the lateral flow assays market is segmented into hospitals & clinics, diagnostic laboratories, home care settings, pharmaceutical & biotechnology companies, and other end users. The hospitals & clinics segment accounted for the largest market share in 2020. Technological advancements, the increasing adoption of point-of-care testing and growing patient inclination toward fast and early diagnosis are driving the growth of the hospitals & clinics segment.

“North America accounted for the largest share of the lateral flow assays market in 2020”

The North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the lateral flow assays market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. However, the APAC is expected to grow at the highest CAGR during the forecast period. The rapidly developing healthcare industry in China and India, growth in the aging population reasons for high growth rate in the lateral flow assays market in this region.

Geographic Snapshot: Lateral Flow Assays Market

Lateral Flow Assays Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players :

The prominent players in the global lateral flow assays market include Abbott Laboratories (US), Quidel Corporation (US), F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), Siemens AG (Germany), BD (US), bioMιrieux SA (France), Bio-Rad Laboratories (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), and Merck KGaA (Germany).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

:

Report Metric

Details

Market Size Available for Years

2019–2026

Base Year Considered

2020

Forecast Period

2022–2026

Forecast Unit

Value (USD Billion)

Segments Covered

By Product type, Application type, Technique type, Sample type, End User and Region

Countries Covered

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa

Companies Covered

Abbott Laboratories (US), Quidel Corporation (US), F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), Siemens AG (Germany), BD (US), bioMιrieux SA (France), Bio-Rad Laboratories (US), Thermo Fisher Scientific, Inc. (US), PerkinElmer Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), Merck KGaA (Germany) among others

The research report categorizes lateral flow assays market into the following segments and sub-segments:

By Type

  • Kits & Reagents
  • Lateral Flow Readers

By Application

  • Clinical Testing
  • Veterinary Diagnostics
  • Food Safety & Environmental Testing
  • Drug Development & Quality Testing

By Technique

  • Sandwich Assays
  • Competitive Assays
  • Multiplex Detection Assays

By Sample Type

  • Blood Samples
  • Urine Samples
  • Saliva Samples
  • Other Samples

By End User

  • Hospitals & Clinics
  • Diagnostics Laboratories
  • Home Care Settings
  • Pharmaceuticals & Biotechnology Companies
  • Other End USer

By Country

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa

Recent Developments:

  • In August 2021, Becton, Dickinson and Company got approval for the OTC rapid antigen test using the Scanwell Health Mobile App.
  • In April 2021, Becton, Dickinson and Company partnered with USA Track & Filed (USATF) (US) to provide rapid COVID-19 testing for athletes using the BD veritor plus system.
  • In September 2020, Qiagen N.V. (Netherlands) acquired NeuMoDx Molecular, Inc. (US) to broaden Qiagen’s diagnostics instrument product portfolio and strengthen its automated molecular testing market position.
  • In July 2020, Merck KGaA (Germany) announced its expansion of a new manufacturing facility worth USD 21 million in Buchs (Switzerland).

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 48)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS IN THE LATERAL FLOW ASSAYS MARKET
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
                    FIGURE 1 LATERAL FLOW ASSAYS MARKET SEGMENTATION
                    FIGURE 2 LATERAL FLOW ASSAYS MARKET, BY REGION
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
          TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 54)
    2.1 RESEARCH APPROACH
          FIGURE 3 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Breakdown of primaries
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
          FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2020)
          FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAYS MARKET (2020)
          FIGURE 7 APPROACH 3: DEMAND-SIDE APPROACH, BASED ON THE MALARIA LATERAL FLOW TESTING MARKET SIZE (2020)
          FIGURE 8 APPROACH 4: TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN & DATA TRIANGULATION
          FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.4 KEY INDUSTRY INSIGHTS
    2.5 LIMITATIONS
           2.5.1 METHODOLOGY-RELATED LIMITATIONS
    2.6 RISK ASSESSMENT
    2.7 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 66)
    FIGURE 10 LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
    FIGURE 11 LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 CLINICAL TESTING LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE,  2021 VS. 2026 (USD MILLION)
    FIGURE 14 LATERAL FLOW ASSAYS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAYS MARKET

4 PREMIUM INSIGHTS (Page No. - 71)
    4.1 LATERAL FLOW ASSAYS MARKET OVERVIEW
          FIGURE 16 RISING COVID-19 PATIENT POPULATION AND GROWTH IN THE PREVALENCE OF INFECTIOUS DISEASES ARE DRIVING THE GROWTH OF THE LATERAL FLOW ASSAYS MARKET
    4.2 REGIONAL MIX: LATERAL FLOW ASSAYS MARKET
          FIGURE 17 APAC TO REGISTER THE HIGHEST CAGR OF -4.07% DURING THE FORECAST PERIOD
    4.3 ASIA PACIFIC LATERAL FLOW ASSAYS MARKET, BY APPLICATION AND COUNTRY
          FIGURE 18 CLINICAL TESTING SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN ASIA PACIFIC
    4.4 LATERAL FLOW ASSAYS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
          FIGURE 19 CHINA TO REGISTER HIGHEST GROWTH RATES DURING THE FORECAST PERIOD
    4.5 LATERAL FLOW ASSAYS MARKET: DEVELOPING VS DEVELOPED COUNTRIES
          FIGURE 20 DEVELOPING COUNTRIES TO OFFER HIGHER GROWTH

5 MARKET OVERVIEW (Page No. - 75)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 High prevalence of infectious diseases across the globe
                                FIGURE 21 PREVALENCE OF INFECTIOUS DISEASES WORLDWIDE
                                TABLE 2 PREVALENCE OF HIV WORLDWIDE (2017 VS. 2020)
                    5.2.1.2 Rapidly increasing geriatric population
                                FIGURE 22 GERIATRIC POPULATION, BY REGION, 2020 VS. 2050 (MILLION)
                                FIGURE 23 GERIATRIC POPULATION, BY COUNTRY, 2020 VS. 2060 (MILLION)
                    5.2.1.3 Growing usage of home-based lateral flow assay devices
                    5.2.1.4 Growing demand for point-of-care testing
                    5.2.1.5 Need for rapid diagnostic testing for COVID-19
                                FIGURE 24 NUMBER OF CONFIRMED CASES OF COVID-19, BY WHO REGION (MILLION)
           5.2.2 RESTRAINTS
                    5.2.2.1 Inconsistent results of lateral flow assay tests
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Evolving applications of lateral flow assays
                                TABLE 3 LIST OF COMMERCIALLY AVAILABLE SALIVA LFA PRODUCTS
                    5.2.3.2 Rising demand for lateral flow assays in the food & beverage industry
                               5.2.3.2.1 Omicron – The new variant of concern is An opportunity for the lateral flow assays market
                                              TABLE 4 EPIDEMIOLOGICAL UPDATE ON THE OMICRON VARIANT
                               5.2.3.2.2 Government initiatives for omicron
                               5.2.3.2.3 Initiatives of Medical diagnostic companies for omicron
                                              TABLE 5 EXAMPLES OF LATERAL FLOW ASSAY KITS AVAILABLE FOR THE DETECTION OF OMICRON
           5.2.4 CHALLENGES
                    5.2.4.1 Limited reimbursements for lateral flow assay products
                    5.2.4.2 Difficulties in procuring quality raw materials for the development of lateral flow assay tests
    5.3 COVID-19 ECONOMIC ASSESSMENT
    5.4 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
          FIGURE 25 CRITERIA IMPACTING THE GLOBAL ECONOMY
          FIGURE 26 COVID-19 SCENARIO BASED FORECAST
    5.5 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAYS MARKET
    5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN LATERAL FLOW ASSAYS MARKET
          FIGURE 27 YC–YCC SHIFT IN LATERAL FLOW ASSAYS MARKET
    5.7 AVERAGE SELLING PRICE TREND
          TABLE 6 AVERAGE SELLING PRICE OF LATERAL FLOW ANALYZERS, BY REGION, 2020
          TABLE 7 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAYS (KITS & REAGENTS)
    5.8 ECOSYSTEM MARKET MAP
          FIGURE 28 ECOSYSTEM: LATERAL FLOW ASSAYS MARKET (2020)
    5.9 PATENT ANALYSIS
           5.9.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAY
                    FIGURE 29 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAYS MARKET, 2016-2021
           5.9.2 TOP APPLICANTS (COMPANIES) OF LATERAL FLOW ASSAYS PATENTS
                    FIGURE 30 TOP COMPANIES THAT APPLIED FOR LATERAL FLOW ASSAYS PATENTS, 2016–2021
           5.9.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN LATERAL FLOW ASSAYS MARKET
                    FIGURE 31 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS PATENTS, 2016–2021
    5.10 VALUE CHAIN ANALYSIS
          FIGURE 32 LATERAL FLOW ASSAYS MARKET: VALUE CHAIN ANALYSIS (2020)
    5.11 TECHNOLOGY ANALYSIS
           5.11.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS
           5.11.2 ADJACENT TECHNOLOGY: ELISA (ENZYME-LINKED IMMUNOSORBENT ASSAYS)
    5.12 CASE STUDY ANALYSIS
    5.13 REGULATORY LANDSCAPE
           TABLE 8 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION
           5.13.1 NORTH AMERICA
           5.13.2 EUROPE
           5.13.3 ASIA
                    5.13.3.1 India
                    5.13.3.2 China
                    5.13.3.3 Japan
    5.14 PORTER’S FIVE FORCES ANALYSIS
           TABLE 9 LATERAL FLOW ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.14.1 THREAT FROM NEW ENTRANTS
           5.14.2 THREAT FROM SUBSTITUTES
           5.14.3 BARGAINING POWER OF SUPPLIERS
           5.14.4 BARGAINING POWER OF BUYERS
           5.14.5 INTENSITY OF COMPETITIVE RIVALRY
    5.15 ADJACENT MARKET ANALYSIS

6 LATERAL FLOW ASSAYS MARKET, BY PRODUCT (Page No. - 102)
    6.1 INTRODUCTION
          TABLE 10 LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
    6.2 KITS & REAGENTS
           6.2.1 INCREASING DEMAND FOR POC TESTING IS DRIVING THE DEMAND FOR KITS & REAGENTS IN THE LATERAL FLOW ASSAYS MARKET
                    TABLE 11 LATERAL FLOW KITS & REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3 LATERAL FLOW ASSAYS READERS MARKET
          TABLE 12 EXAMPLES OF LATERAL FLOW READERS AVAILABLE IN THE MARKET
          TABLE 13 LATERAL FLOW ASSAY KITS & REAGENTS: WITH AND WITHOUT ANALYZERS
          TABLE 14 LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 15 LATERAL FLOW READERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           6.3.1 DIGITAL/HANDHELD READERS
                    6.3.1.1 Technological advancements and high accuracy are the major factors driving the growth of the digital/handheld reader’s market
                                TABLE 16 DIGITAL/HANDHELD LATERAL FLOW READERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                TABLE 17 DIGITAL/HANDHELD LATERAL FLOW READERS MARKET, BY REGION, 2019–2026 (THOUSAND UNITS)
           6.3.2 BENCHTOP READERS
                    6.3.2.1 Lower diagnosis cost per patient is driving the benchtop readers market
                                TABLE 18 BENCHTOP LATERAL FLOW READERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
                                TABLE 19 BENCHTOP LATERAL FLOW READERS VOLUME, REGION, 2019–2026 (THOUSAND UNITS)
    6.4 INSIGHTS ON DISPOSABLE AND REUSABLE LATERAL FLOW ASSAY READERS
    6.5 LATERAL FLOW ASSAYS READERS MARKETS FOR CLINICAL DIAGNOSTICS APPLICATIONS, BY TYPE
           6.5.1 PRODUCT PORTFOLIO ANALYSIS OF LATERAL FLOW ASSAYS READERS FOR CLINICAL DIAGNOSTICS APPLICATION
                    TABLE 20 PRODUCT PORTFOLIO ANALYSIS OF LATERAL FLOW ASSAYS READERS FOR CLINICAL DIAGNOSTICS APPLICATION
                    FIGURE 33 PRODUCT PORTFOLIO ANALYSIS OF LATERAL FLOW ASSAYS READERS FOR CLINICAL DIAGNOSTICS (2020)

7 LATERAL FLOW ASSAYS MARKET, BY APPLICATION (Page No. - 115)
    7.1 INTRODUCTION
          TABLE 21 LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
    7.2 CLINICAL TESTING
          TABLE 22 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2019–2026 (USD MILLION)
          TABLE 23 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY COUNTRY,  2019–2026 (USD MILLION)
           7.2.1 INFECTIOUS DISEASE TESTING
                    TABLE 24 LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                    TABLE 25 LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.1.1 Mosquito-borne diseases
                               7.2.1.1.1 Increasing incidence of dengue is driving the growth of the lateral flow assays market for mosquito-borne diseases
                                              TABLE 26 MAJOR PRODUCTS: DENGUE TESTING
                                              TABLE 27 LATERAL FLOW ASSAYS MARKET FOR MOSQUITO-BORNE DISEASES,  BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.1.2 COVID-19
                               7.2.1.2.1 The ongoing COVID-19 pandemic to drive the demand for rapid lateral flow tests
                                              TABLE 28 COVID-19 (ANTIGEN AND ANTIBODY) LATERAL FLOW ASSAY TESTS
                                              TABLE 29 LATERAL FLOW ASSAYS MARKET FOR COVID-19, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.1.3 Influenza
                               7.2.1.3.1 Growing prevalence of influenza globally is expected to boost market growth
                                              TABLE 30 LATERAL FLOW ASSAYS MARKET FOR INFLUENZA, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.1.4 Sexually transmitted infections
                                TABLE 31 LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                TABLE 32 LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.1.4.1 HIV
                                             7.2.1.4.1.1 Growing awareness about HIV POC testing is one of the major factors driving market growth
                                                              TABLE 33 LATERAL FLOW ASSAYS MARKET FOR HIV, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.1.4.2 HPV
                                             7.2.1.4.2.1 Rising adoption of HPV testing to drive the market during the forecast period
                                                              TABLE 34 LATERAL FLOW ASSAYS MARKET FOR HPV, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.1.4.3 Chlamydia
                                             7.2.1.4.3.1 Growing incidence of chlamydia and rising awareness among patients drive market growth
                                                              TABLE 35 LATERAL FLOW ASSAYS MARKET FOR CHLAMYDIA, BY COUNTRY, 2019–2026
                               7.2.1.4.4 Gonorrhea
                                             7.2.1.4.4.1 Rising incidence of gonorrhea globally and increased funding for R&D to drive the lateral flow assays market during the forecast period
                                                              TABLE 36 LATERAL FLOW ASSAYS MARKET FOR GONORRHEA, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.1.4.5 Syphilis
                                             7.2.1.4.5.1 Growing adoption of novel technologies supporting the growth of the lateral flow assays market for syphilis testing
                                                              TABLE 37 LATERAL FLOW ASSAYS MARKET FOR SYPHILIS, BY COUNTRY, 2019–2026 (USD MILLION)
                               7.2.1.4.6 Other sexually transmitted infections
                                              TABLE 38 LATERAL FLOW ASSAYS MARKET FOR OTHER SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.1.5 Hepatitis
                               7.2.1.5.1 Nucleic acid hybridization-based lateral flow assays hold great potential in the hepatitis testing market
                                              TABLE 39 LATERAL FLOW ASSAYS MARKET FOR HEPATITIS, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.1.6 Tuberculosis
                               7.2.1.6.1 Rising prevalence and growing focus on early diagnosis and treatment drive the market
                                              TABLE 40 LATERAL FLOW ASSAYS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.1.7 Other infectious diseases
                                TABLE 41 LATERAL FLOW ASSAYS MARKET FOR OTHER INFECTIOUS DISEASES,  BY COUNTRY, 2019–2026 (USD MILLION)
           7.2.2 CARDIAC MARKER TESTING
                    TABLE 42 LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 43 LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.2.1 Troponin I & T
                               7.2.2.1.1 Introduction of high-sensitivity troponin assays to drive this market during the forecast period
                                              TABLE 44 LATERAL FLOW ASSAYS MARKET FOR TROPONIN I & T TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.2.2 CK-MB
                               7.2.2.2.1 Growing applications of lateral flow tests in acute myocardial injuries to drive this market
                                              TABLE 45 LATERAL FLOW ASSAYS MARKET FOR CK-MB TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.2.3 BNP and NT-proBNP
                               7.2.2.3.1 Increasing demand for cardiac biomarker tests to detect heart stress and damage to drive growth in this market
                                              TABLE 46 LATERAL FLOW ASSAYS MARKET FOR BNP & NT-PROBNP TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.2.4 Myoglobin
                               7.2.2.4.1 Availability of new high-sensitivity cardiac troponin assays to restrict the growth of the routine myoglobin testing market
                                              TABLE 47 LATERAL FLOW ASSAYS MARKET FOR MYOGLOBIN TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.2.5 D-Dimer
                               7.2.2.5.1 Rising incidence of cardiovascular diseases to drive the market for D-dimer tests
                                              TABLE 48 LATERAL FLOW ASSAYS MARKET FOR D-DIMER TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.2.6 Other cardiac markers
                                TABLE 49 LATERAL FLOW ASSAYS MARKET FOR OTHER CARDIAC MARKER TESTS, BY COUNTRY, 2019–2026 (USD MILLION)
           7.2.3 PREGNANCY & FERTILITY TESTING
                    TABLE 50 LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 51 LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.3.1 Pregnancy testing
                               7.2.3.1.1 Pregnancy testing is among the most common application areas for lateral flow assays, registering slower growth during the forecast period
                                              TABLE 52 LATERAL FLOW ASSAYS MARKET FOR PREGNANCY TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
                    7.2.3.2 Fertility testing
                               7.2.3.2.1 Rising infertility rates across the globe driving the demand for POC fertility testing kits
                                              TABLE 53 LATERAL FLOW ASSAYS MARKET FOR FERTILITY TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
           7.2.4 CHOLESTEROL/LIPID TESTING
                    7.2.4.1 Growing prevalence of obesity and CVD is the key factor driving market growth
                                TABLE 54 LATERAL FLOW ASSAYS MARKET FOR CHOLESTEROL/LIPID TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
           7.2.5 DRUGS-OF-ABUSE TESTING
                    7.2.5.1 Technological advancements and growing focus on workplace drug testing are driving market growth
                                TABLE 55 LATERAL FLOW ASSAYS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
           7.2.6 OTHER CLINICAL TESTS
                    TABLE 56 LATERAL FLOW ASSAYS MARKET FOR OTHER CLINICAL TESTS, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 VETERINARY DIAGNOSTICS
           7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH
                    TABLE 57 LATERAL FLOW ASSAYS MARKET FOR VETERINARY DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
    7.4 FOOD SAFETY & ENVIRONMENT TESTING
           7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING
                    TABLE 58 LATERAL FLOW ASSAYS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
    7.5 DRUG DEVELOPMENT & QUALITY TESTING
           7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE IS DRIVING THE GROWTH OF THIS MARKET
                    TABLE 59 LATERAL FLOW ASSAYS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING, BY COUNTRY, 2019–2026 (USD MILLION)

8 LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE (Page No. - 157)
    8.1 INTRODUCTION
          TABLE 60 LATERAL FLOW ASSAY KITS AND REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
    8.2 SANDWICH ASSAYS
           8.2.1 WIDE APPLICATIONS OF SANDWICH ASSAYS IN CLINICAL TESTING CONTRIBUTE TO THE LARGEST SHARE OF THIS SEGMENT
                    TABLE 61 LATERAL FLOW SANDWICH ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 COMPETITIVE ASSAYS
           8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER GROWTH
                    TABLE 62 LATERAL FLOW COMPETITIVE ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 MULTIPLEX DETECTION ASSAYS
           8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE THE GROWTH OF THIS MARKET
                    TABLE 63 LATERAL FLOW MULTIPLEX DETECTION ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

9 LATERAL FLOW ASSAYS FOR CLINICAL TESTING MARKET, BY SAMPLE TYPE (Page No. - 162)
    9.1 INTRODUCTION
          TABLE 64 LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
    9.2 BLOOD SAMPLES
           9.2.1 INCREASING USE OF BLOOD SAMPLES FOR INFECTIOUS DISEASE TESTING TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 65 LATERAL FLOW ASSAYS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 URINE SAMPLES
           9.3.1 GROWING USE OF URINE SAMPLES FOR PREGNANCY TESTING AND DRUGS-OF-ABUSE TESTING TO DRIVE THE GROWTH OF THIS MARKET
                    TABLE 66 LATERAL FLOW ASSAYS MARKET FOR URINE SAMPLES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 SALIVA SAMPLES
           9.4.1 EASY AND LOW-COST COLLECTION, TRANSPORT, AND ANALYSIS OF SALIVA SAMPLES ARE THE KEY FACTORS DRIVING MARKET GROWTH
                    TABLE 67 LATERAL FLOW ASSAYS MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.5 OTHER SAMPLES
          TABLE 68 CLINICAL TESTING LATERAL FLOW ASSAYS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2019–2026 (USD MILLION)

10 LATERAL FLOW ASSAYS MARKET, BY END USER (Page No. - 168)
     10.1 INTRODUCTION
             TABLE 69 LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.2 HOSPITALS & CLINICS
             10.2.1 INCREASING USE OF POC TESTS DRIVING THE ADOPTION OF LATERAL FLOW ASSAYS AMONG HOSPITALS & CLINICS
                        TABLE 70 LATERAL FLOW ASSAYS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)
     10.3 DIAGNOSTIC LABORATORIES
             10.3.1 LABORATORY TESTING IS LARGELY PREFERRED OVER PROFESSIONAL SETTINGS FOR URINE AND BLOOD TESTING—A KEY FACTOR DRIVING MARKET GROWTH
                        TABLE 71 LATERAL FLOW ASSAYS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
     10.4 HOME CARE SETTINGS
             10.4.1 GROWING ACCEPTANCE OF REMOTE MONITORING DRIVING THE GROWTH OF THE LATERAL FLOW ASSAYS MARKET FOR HOME CARE
                        TABLE 72 LATERAL FLOW ASSAYS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2019–2026 (USD MILLION)
     10.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
             10.5.1 INCREASING FOCUS ON PRODUCT SAFETY TO DRIVE THE USE OF LATERAL FLOW ASSAYS AMONG PHARMACEUTICAL & BIOTECH COMPANIES
                        TABLE 73 LATERAL FLOW ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
     10.6 OTHER END USERS
             TABLE 74 LATERAL FLOW ASSAYS MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)

11 LATERAL FLOW ASSAYS MARKET, BY REGION (Page No. - 176)
     11.1 INTRODUCTION
             FIGURE 34 US TO DOMINATE THE LATERAL FLOW ASSAYS MARKET DURING THE FORECAST PERIOD
             TABLE 75 LATERAL FLOW ASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)
     11.2 NORTH AMERICA
             TABLE 76 NORTH AMERICA: MACROECONOMIC INDICATORS
             FIGURE 35 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET SNAPSHOT
             TABLE 77 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 78 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 79 NORTH AMERICA: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 80 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION,  2019–2026 (USD MILLION)
             TABLE 81 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 82 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
             TABLE 83 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 84 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 85 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 86 NORTH AMERICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
             TABLE 87 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
             TABLE 88 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.2.1 US
                        11.2.1.1 The US accounts for the largest share of the lateral flow assays market in North America
                                      TABLE 89 US: MACROECONOMIC INDICATORS
                                      TABLE 90 US: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                      TABLE 91 US: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 92 US: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 93 US: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 94 US: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 95 US: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 96 US: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 97 US: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 98 US: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                                      TABLE 99 US: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 100 US: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Availability of research funding and implementation of favorable government initiatives are driving the market in Canada
                                      TABLE 101 CANADA: MACROECONOMIC INDICATORS
                                      TABLE 102 CANADA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                      TABLE 103 CANADA: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 104 CANADA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 105 CANADA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 106 CANADA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 107 CANADA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 108 CANADA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 109 CANADA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 110 CANADA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                                      TABLE 111 CANADA: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 112 CANADA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.3 EUROPE
             FIGURE 36 EUROPE: LATERAL FLOW ASSAYS MARKET SNAPSHOT
             TABLE 113 EUROPE: LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 114 EUROPE: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 115 EUROPE: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 116 EUROPE: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 117 EUROPE: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 118 EUROPE: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
             TABLE 119 EUROPE: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 120 EUROPE: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 121 EUROPE: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 122 EUROPE: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
             TABLE 123 EUROPE: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE,  2019–2026 (USD MILLION)
             TABLE 124 EUROPE: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Growing number of POC diagnostics centers to drive the demand for lateral flow assays in Germany
                                      TABLE 125 GERMANY: MACROECONOMIC INDICATORS
                                      TABLE 126 GERMANY: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                      TABLE 127 GERMANY: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 128 GERMANY: LATERAL FLOW ASSAYS MARKET, BY APPLICATION,  2019–2026 (USD MILLION)
                                      TABLE 129 GERMANY: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 130 GERMANY: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 131 GERMANY: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 132 GERMANY: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 133 GERMANY: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 134 GERMANY: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                                      TABLE 135 GERMANY: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 136 GERMANY: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.2 FRANCE
                        11.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France
                                      TABLE 137 FRANCE: MACROECONOMIC INDICATORS
                                      TABLE 138 FRANCE: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                      TABLE 139 FRANCE: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 140 FRANCE: LATERAL FLOW ASSAYS MARKET, BY APPLICATION,  2019–2026 (USD MILLION)
                                      TABLE 141 FRANCE: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 142 FRANCE: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 143 FRANCE: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 144 FRANCE: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 145 FRANCE: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 146 FRANCE: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                                      TABLE 147 FRANCE: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 148 FRANCE: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Increasing incidence of chronic diseases and rising prevalence of obesity propelling the market growth in the UK
                                      TABLE 149 UK: MACROECONOMIC INDICATORS
                                      TABLE 150 UK: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                      TABLE 151 UK: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 152 UK: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 153 UK: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 154 UK: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 155 UK: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 156 UK: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 157 UK: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 158 UK: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                                      TABLE 159 UK: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 160 UK: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Growing initiatives towards the decentralization of medical services in Italy are contributing to market growth
                                      TABLE 161 ITALY: MACROECONOMIC INDICATORS
                                      TABLE 162 ITALY: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,  2019–2026 (USD MILLION)
                                      TABLE 163 ITALY: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 164 ITALY: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 165 ITALY: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 166 ITALY: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 167 ITALY: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 168 ITALY: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 169 ITALY: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 170 ITALY: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                                      TABLE 171 ITALY: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 172 ITALY: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth
                                      TABLE 173 SPAIN: MACROECONOMIC INDICATORS
                                      TABLE 174 SPAIN: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                      TABLE 175 SPAIN: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 176 SPAIN: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 177 SPAIN: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 178 SPAIN: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 179 SPAIN: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 180 SPAIN: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 181 SPAIN: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 182 SPAIN: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                                      TABLE 183 SPAIN: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 184 SPAIN: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.6 REST OF EUROPE
                        TABLE 185 ROE: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 186 ROE: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 187 ROE: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 188 ROE: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 189 ROE: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                        TABLE 190 ROE: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 191 ROE: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING,  BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 192 ROE: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 193 ROE: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                        TABLE 194 ROE: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                        TABLE 195 ROE: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.4 ASIA PACIFIC
             FIGURE 37 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET SNAPSHOT
             TABLE 196 APAC: LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 197 APAC: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 198 APAC: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 199 APAC: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 200 APAC: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 201 APAC: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
             TABLE 202 APAC: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 203 APAC: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 204 APAC: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 205 APAC: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
             TABLE 206 APAC: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
             TABLE 207 APAC: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.1 JAPAN
                        11.4.1.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assays market in Japan
                                      TABLE 208 JAPAN: MACROECONOMIC INDICATORS
                                      TABLE 209 JAPAN: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                      TABLE 210 JAPAN: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 211 JAPAN: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 212 JAPAN: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 213 JAPAN: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 214 JAPAN: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 215 JAPAN: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 216 JAPAN: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 217 JAPAN: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                                      TABLE 218 JAPAN: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE,  2019–2026 (USD MILLION)
                                      TABLE 219 JAPAN: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.2 CHINA
                        11.4.2.1 Growing adoption of lateral flow assays in veterinary diagnostics and drug development is expected to drive market growth in China
                                      TABLE 220 CHINA: MACROECONOMIC INDICATORS
                                      TABLE 221 CHINA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                      TABLE 222 CHINA: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 223 CHINA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 224 CHINA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 225 CHINA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 226 CHINA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 227 CHINA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING,  BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 228 CHINA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 229 CHINA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                                      TABLE 230 CHINA: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 231 CHINA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Increasing prevalence of chronic disorders, growing healthcare concerns, and rising income levels to propel the growth of this market
                                      TABLE 232 INDIA: MACROECONOMIC INDICATORS
                                      TABLE 233 INDIA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                      TABLE 234 INDIA: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 235 INDIA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 236 INDIA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 237 INDIA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 238 INDIA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 239 INDIA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 240 INDIA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 241 INDIA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                                      TABLE 242 INDIA: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 243 INDIA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.4 AUSTRALIA
                        11.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assays market
                                      TABLE 244 AUSTRALIA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                      TABLE 245 AUSTRALIA: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 246 AUSTRALIA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 247 AUSTRALIA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 248 AUSTRALIA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 249 AUSTRALIA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 250 AUSTRALIA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 251 AUSTRALIA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 252 AUSTRALIA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                                      TABLE 253 AUSTRALIA: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 254 AUSTRALIA: LATERAL FLOW ASSAYS MARKET, BY END USER,  2019–2026 (USD MILLION)
             11.4.5 REST OF ASIA PACIFIC
                        TABLE 255 ROAPAC: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 256 ROAPAC: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 257 ROAPAC: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 258 ROAPAC: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 259 ROAPAC: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                        TABLE 260 ROAPAC: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 261 ROAPAC: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 262 ROAPAC: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 263 ROAPAC: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                        TABLE 264 ROAPAC: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                        TABLE 265 ROAPAC: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.5 LATIN AMERICA
             TABLE 266 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 267 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 268 LATIN AMERICA: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 269 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 270 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 271 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
             TABLE 272 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 273 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 274 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 275 LATIN AMERICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
             TABLE 276 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
             TABLE 277 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.5.1 BRAZIL
                        11.5.1.1 High private healthcare expenditure and increasing geriatric population driving the growth of the lateral flow assays market in the country
                                      TABLE 278 BRAZIL: MACROECONOMIC INDICATORS
                                      TABLE 279 BRAZIL: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                      TABLE 280 BRAZIL: LATERAL FLOW READERS MARKET, BY TYPE,  2019–2026 (USD MILLION)
                                      TABLE 281 BRAZIL: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 282 BRAZIL: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 283 BRAZIL: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 284 BRAZIL: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 285 BRAZIL: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING,  BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 286 BRAZIL: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 287 BRAZIL: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                                      TABLE 288 BRAZIL: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE,  2019–2026 (USD MILLION)
                                      TABLE 289 BRAZIL: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.5.2 MEXICO
                        11.5.2.1 High prevalence of obesity and related chronic diseases to boost the growth of the lateral flow assays market in the forecast period
                                      TABLE 290 MEXICO: MACROECONOMIC INDICATORS
                                      TABLE 291 MEXICO: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                      TABLE 292 MEXICO: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 293 MEXICO: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                      TABLE 294 MEXICO: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 295 MEXICO: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 296 MEXICO: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 297 MEXICO: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 298 MEXICO: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                                      TABLE 299 MEXICO: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                                      TABLE 300 MEXICO: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                                      TABLE 301 MEXICO: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.5.3 REST OF LATIN AMERICA
                        TABLE 302 ROLATAM: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 303 ROLATAM: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 304 ROLATAM: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 305 ROLATAM: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 306 ROLATAM: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                        TABLE 307 ROLATAM: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 308 ROLATAM: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 309 ROLATAM: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 310 ROLATAM: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                        TABLE 311 ROLATAM: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                        TABLE 312 ROLATAM: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA
             11.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANSION OF HEALTHCARE SERVICES IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAYS
                        TABLE 313 AFRICA: MACROECONOMIC INDICATORS
                        TABLE 314 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 315 MIDDLE EAST & AFRICA: LATERAL FLOW READERS MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 316 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 317 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 318 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2019–2026 (USD MILLION)
                        TABLE 319 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 320 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2029–2026 (USD MILLION)
                        TABLE 321 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 322 MIDDLE EAST & AFRICA LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2019–2026 (USD MILLION)
                        TABLE 323 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION)
                        TABLE 324 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2019–2026 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 292)
     12.1 OVERVIEW
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             FIGURE 38 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAYS MARKET
     12.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAYS MARKET
             FIGURE 39 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS IN THE LATERAL FLOW ASSAYS MARKET
     12.4 MARKET SHARE ANALYSIS
             FIGURE 40 LATERAL FLOW ASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
             TABLE 325 LATERAL FLOW ASSAYS MARKET: DEGREE OF COMPETITION
     12.5 R&D ASSESSMENT OF KEY PLAYERS
             FIGURE 41 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAYS MARKET, 2018 VS. 2020
     12.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS
             FIGURE 42 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAYS MARKET (2020)
     12.7 COMPANY EVALUATION QUADRANT
             12.7.1 STARS
             12.7.2 PERVASIVE PLAYERS
             12.7.3 EMERGING LEADERS
             12.7.4 PARTICIPANTS
                        FIGURE 43 LATERAL FLOW ASSAYS MARKET: COMPANY EVALUATION MATRIX, 2020
     12.8 COMPANY EVALUATION QUADRANT FOR SMES & START-UPS
             12.8.1 PROGRESSIVE COMPANIES
             12.8.2 DYNAMIC COMPANIES
             12.8.3 STARTING BLOCKS
             12.8.4 RESPONSIVE COMPANIES
                        FIGURE 44 LATERAL FLOW ASSAYS MARKET: COMPANY EVALUATION MATRIX FOR SMES & START-UPS
     12.9 COMPETITIVE BENCHMARKING
             12.9.1 OVERALL COMPANY FOOTPRINT
                        TABLE 326 OVERALL COMPANY FOOTPRINT (25 COMPANIES)
                        TABLE 327 COMPANY FOOTPRINT: BY PRODUCT (25 COMPANIES)
                        TABLE 328 COMPANY FOOTPRINT: BY TECHNIQUE (25 COMPANIES)
                        TABLE 329 COMPANY FOOTPRINT: BY APPLICATION (25 COMPANIES)
                        TABLE 330 COMPANY FOOTPRINT: BY SAMPLE TYPE (25 COMPANIES)
                        TABLE 331 COMPANY FOOTPRINT: BY END USER (25 COMPANIES)
                        TABLE 332 COMPANY FOOTPRINT: BY REGION (25 COMPANIES)
     12.1 COMPETITIVE SCENARIO
             12.10.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 333 PRODUCT LAUNCHES & APPROVALS, JANUARY 2018–SEPTEMBER 2021
             12.10.2 DEALS
                        TABLE 334 DEALS, JANUARY 2018–SEPTEMBER 2021
             12.10.3 EXPANSIONS
                        TABLE 335 EXPANSIONS, JANUARY 2018–SEPTEMBER 2021

13 COMPANY PROFILES (Page No. - 314)
     13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             13.1.1 ABBOTT LABORATORIES
                        TABLE 336 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 45 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
             13.1.2 F. HOFFMANN-LA ROCHE AG
                        TABLE 337 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
                        FIGURE 46 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)
             13.1.3 QUIDEL CORPORATION
                        TABLE 338 QUIDEL CORPORATION: BUSINESS OVERVIEW
                        FIGURE 47 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)
             13.1.4 DANAHER CORPORATION
                        TABLE 339 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             13.1.5 SIEMENS AG
                        TABLE 340 SIEMENS AG: BUSINESS OVERVIEW
                        FIGURE 49 SIEMENS AG: COMPANY SNAPSHOT (2020)
             13.1.6 BECTON, DICKINSON AND COMPANY
                        TABLE 341 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 50 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
             13.1.7 BIOMΙRIEUX SA
                        TABLE 342 BIOMERIEUX SA: BUSINESS OVERVIEW
                        FIGURE 51 BIOMERIEUX SA: COMPANY SNAPSHOT (2020)
             13.1.8 BIO-RAD LABORATORIES, INC.
                        TABLE 343 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 52 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
             13.1.9 THERMO FISHER SCIENTIFIC INC.
                        TABLE 344 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 53 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
             13.1.10 PERKINELMER INC.
                        TABLE 345 PERKINELMER, INC.: BUSINESS OVERVIEW
                        FIGURE 54 PERKINELMER, INC.: COMPANY SNAPSHOT (2020)
     13.2 OTHER PLAYERS
             13.2.1 QIAGEN N.V.
                        TABLE 346 QIAGEN N. V.: BUSINESS OVERVIEW
                        FIGURE 55 QIAGEN N. V.: COMPANY SNAPSHOT (2020)
             13.2.2 MERCK KGAA
                        TABLE 347 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 56 MERCK KGAA: COMPANY SNAPSHOT (2020)
             13.2.3 HOLOGIC, INC.
                        TABLE 348 HOLOGIC, INC.: BUSINESS OVERVIEW
                        FIGURE 57 HOLOGIC, INC.: COMPANY SNAPSHOT (2020)
             13.2.4 ABCAM PLC
                        TABLE 349 ABCAM PLC: BUSINESS OVERVIEW
                        FIGURE 58 ABCAM PLC.: COMPANY SNAPSHOT (2020)
             13.2.5 SURMODICS IVD
                        TABLE 350 SURMODICS IVD: BUSINESS OVERVIEW
                        FIGURE 59 SURMODICS IVD.: COMPANY SNAPSHOT (2020)
             13.2.6 CHEMBIO DIAGNOSTIC SYSTEMS, INC.
                        TABLE 351 CHEMBIO DIAGNOSTICS SYSTEMS: BUSINESS OVERVIEW
                        FIGURE 60 CHEMBIO DIAGNOSTIC SYSTEMS, INC.: COMPANY SNAPSHOT (2020)
             13.2.7 ORASURE TECHNOLOGIES
                        TABLE 352 ORASURE TECHNOLOGIES: BUSINESS OVERVIEW
                        FIGURE 61 ORASURE TECHNOLOGIES: COMPANY SNAPSHOT (2020)
             13.2.8 DCN DIAGNOSTICS
                        TABLE 353 DCN DIAGNOSTICS: BUSINESS OVERVIEW
             13.2.9 POLYSCIENCES, INC.
                        TABLE 354 POLYSCIENCES, INC.: BUSINESS OVERVIEW
             13.2.10 ABINGDON HEALTH
                        TABLE 355 ABINGDON HEALTH: BUSINESS OVERVIEW
             13.2.11 BIOPORTO DIAGNOSTICS A/S
                        TABLE 356 BIOPORTO DIAGNOSTICS A/S: BUSINESS OVERVIEW
                        FIGURE 62 BIOPORTO DIAGNOSTICS A/S: COMPANY SNAPSHOT (2020)
             13.2.12 MICROCOAT BIOTECHNOLOGIES GMBH
                        TABLE 357 MICROCOAT BIOTECHNOLOGIES GMBH: BUSINESS OVERVIEW
             13.2.13 SCIENION AG
                        TABLE 358 SCIENION AG: BUSINESS OVERVIEW
             13.2.14 SENOVA GMBH
                        TABLE 359 SENOVA GMBH: BUSINESS OVERVIEW
             13.2.15 ACCESS BIO, INC.
                        TABLE 360 ACCESS BIO, INC.: BUSINESS OVERVIEW

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX (Page No. - 392)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This study involved four major approaches in estimating the current lateral flow assays market size. Extensive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the value market. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

This research study involved widespread secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the lateral flow assays market. It was also used to obtain important information about key players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the lateral flow assays market. Primary sources from the demand side include personnel from hospitals, diagnostic labs, pharma companies, and food & beverage companies.

Market Size Estimation

The total size of the lateral flow assays market was arrived at after data triangulation from four different approaches, as mentioned below.

Bottom-up Approach: Revenues of individual companies were gathered from public sources and databases. Shares of the lateral flow assays businesses of leading players were gathered from secondary sources to the extent available. In certain cases, the share of the business unit was ascertained after a detailed analysis of various parameters, including product portfolio, market positioning, selling price, and geographic reach and strength. Individual shares or revenue estimates were validated through expert interviews.

Country level Analysis: The size of the lateral flow assays market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of kits & reagents in the overall lateral flow assays market was obtained from secondary data and validated by primary participants to arrive at the total lateral flow assays market. Primary participants further validated the numbers.

Primary Interviews: As a part of the primary research process, individual respondent insights on the market size and growth were taken during the interview (regional and global, as applicable). All the responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate.

Geographic market assessment (by region & country): The geographic assessment was done using the following approaches:

Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends

Approach 2: Geographic adoption trends for individual product segments by end users and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)

At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall lateral flow assays market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.

Breakdown of Primary Interviews

A breakdown of the primary respondents for lateral flow assays market (supply side) market is provided below:

Lateral Flow Assays Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable.

Approach to derive the market size and estimate market growth

The market rankings for leading players were ascertained after a detailed assessment of their revenues from the lateral flow assays business using secondary data available through paid and unpaid sources. Owing to data limitations, in certain cases, the revenue share was arrived at after a detailed assessment of the product portfolios of major companies and their respective sales performance. At each point, this data was validated through primary interviews with industry experts.

Objectives of the Study

  • To define, describe, analyze, and forecast the lateral flow assays market by product, application, technique, sample type, end user, and region
  • To provide detailed information about the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the lateral flow assays market in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To strategically profile key players in the global lateral flow assays market and comprehensively analyze their core competencies2
  • To track and analyze competitive developments such as product launches, expansions, acquisitions, partnerships, agreements, and other developments of leading players in the global lateral flow assays market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Product Analysis

  • Further breakdown of the kits & reagents segment of the lateral flow assays market
  • Further segmentation of individual product segments by application and end user

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific lateral flow assays market into South Korea, Australia, New Zealand, and others
  • Further breakdown of the Rest of Europe lateral flow assays market into Belgium, Russia, the Netherlands, Switzerland, and others

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)
Report Code
MD 4158
Published ON
Dec, 2021
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Lateral Flow Assays Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved